InVivo BioTech Services

Executive Summary

InVivo BioTech Services GmbH is a well-established German contract development and manufacturing organization (CDMO) founded in 1997, specializing in mammalian cell culture and the production of monoclonal antibodies and recombinant proteins. The company provides end-to-end outsourcing solutions for research, diagnostic, and preclinical applications, serving a diverse global clientele that includes large diagnostics and biopharmaceutical companies as well as academic spin-offs. With a focus on B2B service and a proven track record in delivering high-quality biological reagents, InVivo has built a reputation for reliability and technical expertise in the competitive CDMO market. The company operates from Berlin, Germany, and maintains a strong position in the European biotech services sector. Looking ahead, InVivo is poised to benefit from the growing demand for outsourced biologics manufacturing and the increasing complexity of therapeutic and diagnostic reagents. While the company remains private and does not disclose financial details, its long operating history suggests stable operations. Key growth drivers include expanding its service portfolio to cover emerging modalities such as cell and gene therapy, increasing production capacity to meet client demand, and forming strategic partnerships with biopharma firms. However, as a private company, transparency on upcoming milestones is limited, and the company faces competition from larger global CDMOs. Overall, InVivo represents a steady but not high-growth opportunity in the specialized biologics services niche.

Upcoming Catalysts (preview)

• TBDCapacity Expansion or New Facility Announcement60% success
• TBDStrategic Partnership with a Major Biopharma Company50% success
• TBDLaunch of New Service Line (e.g., Cell & Gene Therapy Support)40% success